Antitumor effects of cardiovascular drugs

Cardiovascular disease (CVD) and oncological diseases are the leading causes of death in the world. The widespread use of cardiovascular drugs makes it important to study their potential antitumor and carcinogenic effects. The article provides information on the most relevant clinical and experimental studies, which have obtained data on possible antitumor or carcinogenic effects of drugs of basic classes used in cardiology. Current information on the use of acetylsalicylic acid to prevent colorectal cancer is discussed, as well as possible antitumor effects of clopidogrel. The results of studies demonstrating the effect of statins on the risk of cancer development in various localizations are presented. The controversial data on the influence of ACE inhibitors and sartans on the risk of lung cancer and other localizations are discussed. The results of research into beta-blockers as adjuvant therapy for breast cancer are analyzed. The results of studies in which data on possible carcinogenic effects of calcium channel blockers and diuretics were obtained are presented. For each discussed class of drugs, presumed mechanisms of antitumor or carcinogenic action are indicated. The need to develop and introduce drugs to reduce cardiovascular and cancer morbidity into clinical practice by influencing the general pathophysiological mechanisms of CVD and cancer is emphasized. Systemic chronic persistent inflammation is a pathogenetic link between aging, atherosclerosis and carcinogenesis. The results of the CANTOS study opened up new perspectives in the treatment of CANTOS and oncological diseases, and provided a powerful incentive for planning and conducting further studies.

1. Jousilahti P., Laatikainen T., Salomaa V., Pietila A., Vartiainen E., Puska P 40-Year CHD Mortality Trends and the Role of Risk Factors in Mortality Decline: The North Karelia Project Experience. Glob Heart. 2016;11(2):207-212. doi: 10.1016/j.gheart.2016.04.004.

2. Cao B., Bray F., Beltran-Sanchez H., Ginsburg O., Soneji S., Soerjomataram I. Benchmarking life expectancy and cancer mortality: global comparison with cardiovascular disease 1981-2010. BMJ. 2017;357:j2765. doi: 10.1136/bmj.j2765.

3. Dagenais G.R., Lsong D.P, Rangarajan S., Lanas F., Lopez-Jaramillo P, Gupta R. et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. 2020;395(10226):785-794. doi: 10.1016/S0140-6736(19)32007-0.

4. Libby P., Kobold S. Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology. Cardiovasc Res. 2019;115(5):824-829. doi: 10.1093/cvr/cvz058.

5. Rose P.W., Watson E.K., Jenkins L.S. Aspirin for prevention of cancer and cardiovascular disease. Br J Gen Pract. 2011;61(587):412-415. doi: 10.3399/bjgp11X578133.

6. Flossmann E., Rothwell P.M. British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573):1603-1613. doi: 10.1016/S0140-6736(07)60747-8.

7. Tsoi K.K.F., Ho J.M.W., Chan F.C.H., Sung JJ.Y. Long-term use of low-dose aspirin for cancer prevention: A 10-year population cohort study in Hong Kong. Int J Cancer. 2019;145(1):267-273. https://doi.org/10.1002/ijc.32083.

8. Lu L., Shi L., Zeng J., Wen Z. Aspirin as a potential modality for the chemo-prevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget. 2017;8(25):40389-40401. doi: 10.18632/oncotarget.16315.

9. Chubak J., Whitlock E.P., Williams S.B., Kamineni A., Burda B.U., Buist D.S., Anderson M.L. Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164(12):814-825. doi: 10.7326/M15-2117.

10. Bibbins-Domingo K.; U.S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(12):836-845. doi: 10.7326/M16-0577.

11. Leader A., Zelikson-Saporta R., Pereg D., Spectre G., Rozovski U., Raanani P et al. The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence. Am J Med. 2017;130(7):826-832. doi: 10.1016/j.amjmed.2017.01.022.

12. Kuan Y.C., Huang K.W., Lin C.L., Luo J.C., Kao C.H. Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus. Cancers (Basel). 2019;11(10). pii: E1468. doi: 10.3390/cancers11101468.

13. Patrignani P, Patrono C. Aspirin, platelet inhibition and cancer prevention. Platelets. 2018;29(8):779-785. doi: 10.1080/09537104.2018.1492105.

14. Chan A.T., Arber N., Burn J., Chia W.K., Elwood P., Hull M.A. et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5(2):164-178. doi: 10.1158/1940-6207.CAPR-11-0391.

15. Undela K., Shah C.S., Mothe R.K. Statin use and risk of cancer: An overview of meta-analyses. World J Meta-Anal. 2017;5(2):41-53. doi: 10.13105/wjma.v5.i2.41.

16. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367(19):1792-1802. doi: 10.1056/NEJMoa1201735.

17. Farooqi M.A.M., Malhotra N., Mukherjee S.D., Sanger S., Dhesy-Thind S.K., Ellis P., Leong D.P. Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2018;13(12):e0209486. doi: 10.1371/journal.pone.0209486.

18. Borgquist S., Broberg P, Tojjar J., Olsson H. Statin use and breast cancer survival - a Swedish nationwide study. BMC Cancer. 2019;19(1):54. doi: 10.1186/s12885-018-5263-z.

19. Beckwitt C.H., Brufsky A., Oltvai Z.N., Wells A. Statin drugs to reduce breast cancer recurrence and mortality. Breast Cancer Res. 2018;20(1):144. doi: 10.1186/s13058-018-1066-z.

20. Gong J., Sachdev E., Robbins L.A., Lin E., Hendifar A.E., Mita, M.M. Statins and pancreatic cancer (Review). Oncology Letters. 2017;13:1035-1040. doi: 10.3892/ol.2017.5572.

21. Shen J., Huang Y.M., Wang M., Hong X.Z., Song X.N., Zou X. et al. Renin-angiotensin system blockade for the risk of cancer and death. J Renin Angiotensin Aldosterone Syst. 2016;17(3). pii: 1470320316656679. doi: 10.1177/1470320316656679.

22. Sun H., Li T., Zhuang R., Cai W., Zheng Y. Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients? Evidence from a meta-analysis including 55 studies. Medicine (Baltimore). 2017;96(13):e6394. doi: 10.1097/MD.0000000000006394.

23. Hicks B.M., Filion K.B., Yin H., Sakr L., Udell J.A., Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209. doi: 10.1136/bmj.k4209.

24. Wang G., Sun J., Liu G., Fu Y., Zhang X. Bradykinin Promotes Cell Proliferation, Migration, Invasion, and Tumor Growth of Gastric Cancer Through ERK Signaling Pathway. J Cell Biochem. 2017;118(12):4444-4453. doi: 10.1002/jcb.26100.

25. Ino K., Shibata K., Kajiyama H., Nawa A., Nomura S., Kikkawa F. Manipulating the angiotensin system-new approaches to the treatment of solid tumours. Expert Opin Biol Ther. 2006;6(3):243-255. doi: 10.1517/14712598.6.3.243.

26. Yap A., Lopez-Olivo M.A., Dubowitz J., Pratt G., Hiller J., Gottumukkala V. et al. Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies. Br J Anaesth. 2018;121(1):45-57. doi: 10.1016/j.bja.2018.03.024.

27. Phadke S., Clamon G. Beta blockade as adjunctive breast cancer therapy: A review. Crit Rev Oncol Hematol. 2019;138:173-177. doi: 10.1016/j.cri-trevonc.2019.04.006.

28. Li C., Li T., Tang R., Yuan S., Zhang W. (3-Blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis. Biosci Rep. 2020;40(6):BSR20200721. doi: 10.1042/BSR20200721.

29. Weberpals J., Jansen L., Carr P.R., Hoffmeister M., Brenner H. Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and meta-analysis. Cancer Treat Rev. 2016;47:1-11. doi: 10.1016/j.ctrv.2016.04.004.

30. Coelho M., Soares-Silva C., Brandao D., Marino F., Cosentino M., Ribeiro L. (3-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives. J Cancer Res Clin Oncol. 2017;143(2):275-291. doi: 10.1007/s00432-016-2278-1.

31. Raebel M.A., Zeng C., Cheetham T.C., Smith D.H., Feigelson H.S., Carroll N.M. et al. Risk of Breast Cancer With Long-Term Use of Calcium Channel Blockers or Angiotensin-Converting Enzyme Inhibitors Among Older Women. Am J Epidemiol. 2017;185(4):264-273. doi: 10.1093/aje/kww217.

32. Grimaldi-Bensouda L., Klungel O., Kurz X., de Groot M.C., Maciel Afonso A.S., de Bruin M.L., Reynolds R., Rossignol M. Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). BMJ Open. 2016;6(1):e009147. doi: 10.1136/bmjopen-2015-009147.

33. Rotshild V., Azoulay L., Zarifeh M., Masarwa R., Hirsh-Raccah B., Perlman A. et al. The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies. Drug Saf. 2018;41(6):555-564. doi: 10.1007/s40264-018-0644-4.

34. Rotshild V., Azoulay L., Feldhamer I., Perlman A., Muszkat M., Matok I. Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Population-Based Nested Case-Control Study. Pharmacotherapy. 2019;39(6):690-696. doi: 10.1002/phar.2266.

35. Wang Z., White D.L., Hoogeveen R., Chen L., Whitsel EA., Richardson PA. et al. Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women's Health Initiative Study. J Clin Med. 2018;7(8)i:E197. doi: 10.3390/jcm7080197.

36. Shin D., Lee E.S., Kim J., Guerra L., Naik D., Prida X. Association Between the Use of Thiazide Diuretics and the Risk of Skin Cancers: A Meta-Analysis of Observational Studies. J Clin Med Res. 2019;11(4):247-255. doi: 10.14740/jocmr3744.

37. Pedersen S.A., Gaist D., Schmidt S.AJ., Holmich L.R., Friis S., Pottegard A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673-681.e9. doi: 10.1016/j.jaad.2017.11.042.

38. Mackenzie I.S., Morant S.V., Wei L., Thompson A.M., MacDonald T.M. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol. 2017;83(3):653-663. doi: 10.1111/bcp.13152

39. Gold A., Eini L., Nissim-Rafinia M., Viner R., Ezer S., Erez K. et al. Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response. Oncogene. 2019;38(17):3103-3118. doi: 10.1038/s41388-018-0654-9.

40. Libby P., Kobold S. Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology. Cardiovasc Res. 2019;115(5):824-829. doi: 10.1093/cvr/cvz058.

41. Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C. et al.; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi: 10.1056/NEJMoa1707914.

42. Ridker P.M., MacFadyen J.G., Thuren T., Everett B.M., Libby P., Glynn RJ. Effect of interleukin-1 в inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833-1842. doi: 10.1016/S0140-6736(17)32247-X.